Skip to content

CRANDELL KEITH

Reporting owner on Forms 3, 4 and 5, CIK 1219039.

CRANDELL KEITH reported on 3 issuers in 9 filings, the latest a 13D/A filed 2026-11-13.

Issuers

IssuerRoles in the latest filingFilingsLast filed
LYEL · Lyell Immunopharma, Inc.CIK 180695210% owner12026-11-05
Aspen Neuroscience, Inc. CIK 212408010% owner22026-11-02
CITY THERAPEUTICS, INC. CIK 214385010% owner22026-10-19

Transactions and holdings

Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.

SecurityDateCodeSharesPriceOwned afterFiling
LYEL · Lyell Immunopharma, Inc.Common Stock2026-11-04P bought+2,321,262$10.773,747,790Form 4
LYEL · Lyell Immunopharma, Inc.Common Stock, holding 910,317Form 4
LYEL · Lyell Immunopharma, Inc.Common Stock, holding 910,317Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02P bought+66,666$1566,666Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+187,182253,848Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+298,258552,106Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+286,304838,410Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+295,4901,133,900Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+259,9481,393,848Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02P bought+66,667$1566,667Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+298,258364,925Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+286,304651,229Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+295,490946,719Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02C converted+214,3551,161,074Form 4
Aspen Neuroscience, Inc. Common Stock2026-11-02P bought+1,200,000$151,200,000Form 4
Aspen Neuroscience, Inc. Series Seed Convertible Preferred Stock, derivative2026-11-02C converted-187,1820Form 4
Aspen Neuroscience, Inc. Series A-1 Convertible Preferred Stock, derivative2026-11-02C converted-298,2580Form 4
Aspen Neuroscience, Inc. Series A-1 Convertible Preferred Stock, derivative2026-11-02C converted-298,2580Form 4
Aspen Neuroscience, Inc. Series A-2 Convertible Preferred Stock, derivative2026-11-02C converted-286,3040Form 4
Aspen Neuroscience, Inc. Series A-2 Convertible Preferred Stock, derivative2026-11-02C converted-286,3040Form 4
Aspen Neuroscience, Inc. Series B Convertible Preferred Stock, derivative2026-11-02C converted-295,4900Form 4
Aspen Neuroscience, Inc. Series B Convertible Preferred Stock, derivative2026-11-02C converted-295,4900Form 4
Aspen Neuroscience, Inc. Series C Convertible Preferred Stock, derivative2026-11-02C converted-259,9480Form 4
Aspen Neuroscience, Inc. Series C Convertible Preferred Stock, derivative2026-11-02C converted-214,3550Form 4
Aspen Neuroscience, Inc. Series Seed Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series A-1 Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series A-1 Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series A-2 Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series A-2 Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series B Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series B Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series C Convertible Preferred Stock, derivative, holding Form 3
Aspen Neuroscience, Inc. Series C Convertible Preferred Stock, derivative, holding Form 3
CITY THERAPEUTICS, INC. Common Stock2026-10-19C converted+3,294,9006,013,192Form 4
CITY THERAPEUTICS, INC. Common Stock2026-10-19C converted+5,482,30911,495,501Form 4
CITY THERAPEUTICS, INC. Common Stock2026-10-19C converted+2,027,00613,522,507Form 4
CITY THERAPEUTICS, INC. Common Stock2026-10-19P bought+170,000$1813,692,507Form 4
CITY THERAPEUTICS, INC. Series Seed convertible preferred stock, derivative2026-10-19C converted-3,000,000$00Form 4
CITY THERAPEUTICS, INC. Series A convertible preferred stock, derivative2026-10-19C converted-4,991,633$00Form 4
CITY THERAPEUTICS, INC. Series B convertible preferred stock, derivative2026-10-19C converted-1,845,585$00Form 4
CITY THERAPEUTICS, INC. Common Stock, holding 2,718,292Form 3
CITY THERAPEUTICS, INC. Series Seed convertible preferred stock, derivative, holding Form 3
CITY THERAPEUTICS, INC. Series A convertible preferred stock, derivative, holding Form 3
CITY THERAPEUTICS, INC. Series B convertible preferred stock, derivative, holding Form 3

Filings

The person's Forms 3, 4 and 5, and any 13D or 13G naming it.

FilingSubjectFiledAcceptedIngested
13D/A 0001193125-26-460600 PRME2026-11-13
13D 0001193125-26-454047 ASPE2026-11-09
13D/A 0001012975-26-001020 VIR2026-11-06
Form 4 0001012975-26-001013 Lyell Immunopharma, Inc.2026-11-05
Form 4 0001193125-26-444147 Aspen Neuroscience, Inc.2026-11-02
Form 3 0001193125-26-439136 Aspen Neuroscience, Inc.2026-10-29
13D 0001193125-26-432028 CTY2026-10-26
Form 4 0001104659-26-116966 CITY THERAPEUTICS, INC.2026-10-19
Form 3 0001104659-26-116360 CITY THERAPEUTICS, INC.2026-10-15